Cholangitis

Daily treatment with Ipsen’s elafibranor safely and effectively eases itching, stabilizes liver scarring, and reduces liver damage biomarkers in adults with primary sclerosing…

High blood levels of the antibody immunoglobulin G, or IgG, at diagnosis are linked to a more severe disease course among people with primary…

Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…

Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…

The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health Service (NHS), making the therapy…

A year of treatment with Chemomab Therapeutics’s candidate nebokitug reduces key disease biomarkers and the occurrence of clinical events that reflect disease progression among…

Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…

A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to…

Conscience, a Canadian nonprofit, has awarded CA$461,241 (nearly $320,000) to a research project aiming to provide preclinical data that could lead to new approaches…

“I can’t explain why, but I don’t feel well,” my younger brother, Osari, said. He was 32 years old at the time. That statement was…